CoreAge Rx vs Care Bare Rx
Two partners, two pricing philosophies: a $50 molecule gap against no gap at all.
Disclosure: Buy This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
CoreAge Rx
Partner
$99/mo
Semaglutide is $99 a month and tirzepatide $149, both injectable, with no oral line. Fifty states. These figures were last checked on 5 August 2026, earlier than the rest of this group, so treat them as the oldest reading here.
Pick it for: Buyers who want semaglutide at the lower figure
Care Bare Rx
Partner
$199/mo
Semaglutide and tirzepatide are both $199 a month, injection only. There is no oral line and no price gap between the molecules, so the usual tirzepatide premium does not apply here. Fifty states. The catalog also runs to hair, NAD+ and sexual health.
Pick it for: Buyers who want tirzepatide and refuse to pay a premium for it
Our verdict
CoreAge Rx charges $99 and $149 for the two molecules; Care Bare Rx charges $199 for either. Semaglutide is cheaper at CoreAge, tirzepatide cheaper at Care Bare.
What actually separates them
CoreAge Rx and Care Bare Rx state different things about published price. Everything else they publish, they publish the same way.
Care Bare Rx costs $100 more than CoreAge Rx — 101% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $1,188 at CoreAge Rx against $2,388 at Care Bare Rx — a difference of $1,200.
| CoreAge Rx | Care Bare Rx | |
|---|---|---|
| Published price | $99/mo | $199/mo |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.